Nurix Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
Nurix Therapeutics Return on Equity (ROE) Growth & History (NRIX)
Nurix Therapeutics's return on equity was −49.63% for fiscal 2025.
View full Nurix Therapeutics company overviewNurix Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-11-30 | −49.63% | +3.59 pp |
| 2024 | 2024-11-30 | −53.22% | +3.88 pp |
| 2023 | 2023-11-30 | −57.10% | −1.26 pp |
| 2022 | 2022-11-30 | −55.84% | −18.79 pp |
| 2021 | 2021-11-30 | −37.05% | +0.14 pp |
| 2020 | 2020-11-30 | −37.19% | — |
Nurix Therapeutics quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-05-31 | −20.27% | −10.91 pp |
| Q1 2026 | 2026-02-28 | −17.10% | −5.92 pp |
| Q4 2025 | 2025-11-30 | −17.17% | −4.22 pp |
| Q3 2025 | 2025-08-31 | −21.08% | −7.98 pp |
| Q2 2025 | 2025-05-31 | −9.36% | +7.15 pp |
| Q1 2025 | 2025-02-28 | −11.18% | +11.31 pp |
| Q4 2024 | 2024-11-30 | −12.96% | +6.37 pp |
| Q3 2024 | 2024-08-31 | −13.10% | +1.88 pp |
| Q2 2024 | 2024-05-31 | −16.52% | −7.42 pp |
| Q1 2024 | 2024-02-29 | −22.49% | −8.39 pp |
| Q4 2023 | 2023-11-30 | −19.32% | −4.86 pp |
| Q3 2023 | 2023-08-31 | −14.98% | +0.02 pp |
| Q2 2023 | 2023-05-31 | −9.09% | +6.76 pp |
| Q1 2023 | 2023-02-28 | −14.10% | −0.98 pp |
| Q4 2022 | 2022-11-30 | −14.46% | −3.95 pp |
| Q3 2022 | 2022-08-31 | −15.00% | −7.55 pp |
| Q2 2022 | 2022-05-31 | −15.86% | −7.96 pp |
| Q1 2022 | 2022-02-28 | −13.12% | −4.46 pp |
| Q4 2021 | 2021-11-30 | −10.51% | −3.85 pp |
| Q3 2021 | 2021-08-31 | −7.46% | +7.36 pp |
| Q2 2021 | 2021-05-31 | −7.90% | — |
| Q1 2021 | 2021-02-28 | −8.66% | — |
| Q4 2020 | 2020-11-30 | −6.66% | — |
| Q3 2020 | 2020-08-31 | −14.82% | — |
Nurix Therapeutics return on equity trends
Over the last five fiscal years, Nurix Therapeutics's return on equity decreased from −37.19% to −49.63%, a change of −12.44 percentage points. The latest reported quarter, Q2 2026, shows −20.27%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics source filings ↗